Abrdn Healthcare Investors·Financial Services
Abrdn Healthcare Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the healthcare sector, including the biotechnology, medical devices, and pharmaceuticals industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as current or anticipated market position for services or products, experienced business management, recognized technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotechnology Index, the S&P 500 Index, and the S&P 1500 Healthcare Index. Abrdn Healthcare Investors was formed on October 31, 1986 and is domiciled in the United States.
Financial Services
Asset Management
1987-04-23
0.73

Investors have thousands of choices. Your preferences matter, and knowing what you want sharpens your decision-making. Income-focused discipline creates real clarity and confidence.

PHILADELPHIA, March 31, 2026 /PRNewswire/ -- The Aberdeen Investments U.S. Closed-End Funds (NYSE: ASGI, HQH, HQL, IFN, THQ), (NYSE American: IAF) (the "Funds" or individually the "Fund"), today announced that the Funds paid the distributions noted in the table below on March 31, 2026, on a per share basis to all shareholders of record as of March 24, 2026 (ex-dividend date March 24, 2026). These dates apply to the Funds listed below with the exception of abrdn Healthcare Investors (HQH), abrdn Life Sciences Investors (HQL), abrdn Australia Equity Fund, Inc. (IAF) and Aberdeen India Fund Inc. (IFN) which paid on March 31, 2026, to all shareholders of record as of February 20, 2026 (ex-dividend date February 20, 2026).

Healthcare dividend stocks are selling off with the turbulence in the Middle East.

abrdn Healthcare Investors offers more volatile healthcare exposure, leaning heavily toward biotech, making it riskier than traditional healthcare funds. HQH's 12% managed distribution policy yields high distribution, but sustainability depends on capital gains in a cyclical, boom-bust biotech sub-sector. The fund's discount has narrowed since our last write-up, reducing its relative attractiveness versus historical averages, but it has continued to deliver strong recent performance.

abrdn Healthcare Investors (NYSE: HQH - Get Free Report) saw a significant growth in short interest during the month of February. As of February 13th, there was short interest totaling 191,363 shares, a growth of 361.3% from the January 29th total of 41,483 shares. Based on an average trading volume of 173,847 shares, the days-to-cover ratio

Outsource the Expertise: Don't waste time mastering biotech or commercial debt; use the specialized skills of institutional managers at abrdn Healthcare Investors and Apollo Commercial Real Estate Finance to do it for you. 11.1% Yield in Healthcare: Capitalize on the aging U.S. demographic with HQH, which just declared its highest quarterly dividend since 2015. Ride along with ARI as they convert their $9B loan portfolio into a massive cash pile to hunt for high-return M&A opportunities.